Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry
Portfolio Pulse from Benzinga Insights
AstraZeneca (NASDAQ:AZN) is evaluated against its competitors in the Pharmaceuticals industry. The analysis includes financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. AstraZeneca's P/E, P/B, and P/S ratios are below the industry average, suggesting potential undervaluation. However, its ROE, EBITDA, gross profit, and revenue growth are also below the industry average, indicating possible inefficiencies and lower profitability. The company's lower debt-to-equity ratio compared to its top 4 peers suggests a stronger financial position.
November 27, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AstraZeneca's stock may be undervalued based on P/E, P/B, and P/S ratios, but concerns over profitability and growth potential due to lower ROE, EBITDA, and revenue growth could impact investor sentiment.
The mixed financial indicators present a complex picture for AstraZeneca. While lower valuation ratios typically attract investors looking for undervalued stocks, the lower profitability and growth metrics compared to the industry might deter investors seeking companies with strong financial performance. The short-term impact is likely to be neutral as these opposing factors may balance each other out.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100